Thomas Galloway is an Oncology physician affiliated with Fox Chase Cancer Center. OpenAlex indexes 261 publications with 6,999 citations (h-index 35); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
333 Coltman Avenue
Fox Chase Cancer Center
Philadelphia, PA 19111
Telephone
215-728-6900Registry record last updated 13 Apr 2018.
Clinical trials
- Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer
Sponsor: Fox Chase Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Siemens Medical Solutions USA, Inc.Program year20245 payments
- Merck KGaAProgram year20231 payment
- Kite Pharma, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
81.5%Opioid Agonist25%Oxycodone Hcl76%Tramadol Hcl24%Part D<11 patientsPartial Opioid Agonist23.9%Buprenorphine100%Part D≥19 patients+ 3 more classes in this area
Cardiovascular
10.9%Antiarrhythmic10.9%Lidocaine Hcl Viscous100%Part D≥12 patientsMetabolism & gastrointestinal
7.6%Serotonin-3 Receptor Antagonist7.6%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025
Journal of the National Comprehensive Cancer Network
2025 - Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline
Journal of Clinical Oncology
2025 - International Expert-Based Consensus Definition, Classification Criteria, and Minimum Data Elements for Osteoradionecrosis of the Jaw: An Interdisciplinary Modified Delphi Study
International Journal of Radiation Oncology*Biology*Physics
2025 - NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
Journal of the National Comprehensive Cancer Network
2022 - Pathogenesis and Amelioration of Radiation-Induced Oral Mucositis
Current Treatment Options in Oncology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Elizabeth Plimack, MD
Fox Chase Cancer Center
Robert Uzzo, MD02041967
Fox Chase Cancer Center
John Ridge, MD
Fox Chase Cancer Center
Eric Horwitz, MD
Fox Chase Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”